Adma Biologics (ADMA) Return on Capital Employed (2011 - 2025)
Adma Biologics (ADMA) reported Return on Capital Employed of 36.33% for Q4 2025, up 15.0% on a YoY basis from 31.59% in Q4 2024, and up 10.3% quarter-over-quarter from 32.94% in Q3 2025.
Adma Biologics (ADMA) Return on Capital Employed (2011 - 2025) Analysis & Trends
Adma Biologics has reported Return on Capital Employed for 13 years, with the latest figure at 36.33% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 15.0% year-over-year to 36.33%; the trailing twelve-month figure through Dec 2025 stood at 36.33% (up 15.0% YoY), and the FY2025 full-year result was 39.32%, down 1.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 36.33%, up from 32.94% in the prior quarter.
- The five-year high for Return on Capital Employed was 36.33% in Q4 2025, with the low at 31.58% in Q1 2021.
- Historically, Return on Capital Employed has averaged 2.67% across 5 years, with a median of 2.56% in 2023.
- Annual changes were most pronounced in 2021 — Return on Capital Employed slumped 254 bps — and 2024, when it soared 3349 bps.
- Adma Biologics' Return on Capital Employed stood at 25.71% in 2021, then jumped by 46 bps to 13.8% in 2022, then soared by 154 bps to 7.48% in 2023, then soared by 384 bps to 36.18% in 2024, then advanced by 0 bps to 36.33% in 2025.
- The last three Return on Capital Employed figures came in at 36.33% (Q4 2025), 32.94% (Q3 2025), and 33.87% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Adma Biologics | 1.98 Bn | 1.89 Bn | 88.82 Mn | 36.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36.33% |
| Sep 30, 2025 | 32.94% |
| Jun 30, 2025 | 33.87% |
| Mar 31, 2025 | 34.08% |
| Dec 31, 2024 | 36.18% |
| Sep 30, 2024 | 33.93% |
| Jun 30, 2024 | 26.28% |
| Mar 31, 2024 | 15.43% |
| Dec 31, 2023 | 7.48% |
| Sep 30, 2023 | 0.44% |
| Jun 30, 2023 | -5.55% |
| Mar 31, 2023 | -8.24% |
| Dec 31, 2022 | -13.80% |
| Sep 30, 2022 | -18.28% |
| Jun 30, 2022 | -18.81% |
| Mar 31, 2022 | -22.27% |
| Dec 31, 2021 | -25.71% |
| Sep 30, 2021 | -30.68% |
| Jun 30, 2021 | -28.59% |
| Mar 31, 2021 | -31.58% |